Drugs / Naftopidil
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00967772 | Sep → Oct 2009 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01203371 | Jan → Sep 2011 | hyperplasia | Apsen Farmaceutica S.A. | Withdrawn | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02034604 | Dec 2013 → Dec 2016 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01922375 | Dec 2011 → Sep 2012 | benign prostatic hyperplasia | Dong-A Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT01952314 Comparator | May 2014 → Aug 2015 | ureterolithiasis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01959074 Comparator | May 2014 → Jun 2015 | urinary system disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02011737 Comparator | Feb 2014 → Feb 2015 | nephrolithiasis, ureterolithiasis | Samsung Medical Center | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-05-06 | Dong-A ST Co., Ltd. | Dong-A Signs License Agreement to Exclusively Develop and Market Asahi Kasei’s FLIVAS, a Prostatism Treatment, in Korea donga-st.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Naftopidil | “Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia” NCT02034604 ↗ |
| Known as | Flivas | “safety/tolerability and pharmacokinetics (PK) of Naftopidil (commercial name: Flivas)” NCT00967772 ↗ |
| Known as | NAFTOPIDIL DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL142635 ↗ |
| Known as | NSC-759293 | ChEMBL registry synonym — accepted as the source's own label CHEMBL142635 ↗ |
| Action | Inhibit | “Alpha-1d adrenergic receptor antagonist” CHEMBL142635 ↗ |
| Modality | Small molecule | — CHEMBL142635 ↗ |
| Route | Oral | “after oral administration” NCT00967772 ↗ |
| Target | ADRA1D | “Alpha-1d adrenergic receptor antagonist” CHEMBL142635 ↗ |